The importance of preserving renal function in patients with atrial fibrillation and diabetes

The Kidneys Matter in Patients with Atrial fibrillation and diabetes.

 

PP-M_RIV-ZA-0029

For full prescribing information, refer to the package insert approved by the Medicines Authority (SAHPRA).

XARELTO® 10 (Rivaroxaban 10 mg): South Africa:  S4  Reg. No.: 42/8.2/1046; Namibia:  NS2  10/8.2/0463; Botswana:  S2  BOT1302278; Zimbabwe: PP10 Reg. 2017/10.2/5362; Mauritius: R12697/02/14.

XARELTO® 15 (Rivaroxaban 15 mg): South Africa:  S4  Reg. No.: 46/8.2/0111; Namibia:  NS2  12/8.2/0006; Botswana:  S2  BOT1302278; Zimbabwe: PP10 Reg. 2017/10.2/5363; Mauritius: R11772/02/14.

XARELTO® 20 (Rivaroxaban 20 mg): South Africa:  S4  Reg. No.: 46/8.2/0112; Namibia:  NS2  12/8.2/0007; Botswana:  S2  BOT1302297; Zimbabwe: PP10 Reg. 2017/10.2/5364; Mauritius: R12698/02/14. 

Applicant/HCR: Bayer (Pty) Ltd, Co. Reg. No.: 1968/011192/07, 27 Wrench Road, Isando, 1609.

 

PP-XAR-BW-0019